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Abstract
Background: Mammography is the current standard for breast cancer detection however
magnetic resonance imaging (MRI) is a more sensitive method of breast imaging. Despite MRI’s
increased sensitivity, MRI has more false positives and higher costs. The purpose of this study
was to determine if MRI or MRI in conjunction with mammography was a cost-effective
solution for breast cancer detection in women with average lifetime risk of breast cancer.
Methods: A mathematical model was used to compare annual mammography, annual MRI, and
mammography and MRI on alternate years. The model included the natural history of breast
cancer, screening by mammography and MRI, screening and treatment costs, and health state
utilities. The Surveillance, Epidemiology, and End Results project provided data for the natural
history model. Data from the Breast Cancer Surveillance Consortium and from the literature was
used to model screening. Costs were taken from the Physician Fee Schedule for Medicare and
Medicaid Services (CMS) and from the literature. In particular, mammograms were priced at
$81.35 each and MRIs were priced at $787.23 each. Utilities for stages of breast cancer were
found using Tuft University Cost Effectiveness Analysis Registry
Results: The difference between MRI only and mammography only was $842,297/QALY at the
standard cost of screening found from the CMS. The difference between MRI plus
mammography and mammography only was $749,131/QALY at standard CMS screening costs.
Discussion: Although MRI may have health benefits, at current prices, MRI screening is not a
cost-effective alternative to annual mammography in women age 40 to 80 with average risk of
breast cancer. MRI’s would cost effective at a $50,000 per QALY level if the cost of MRI
screening were comparable to that of mammography.
Background
The most common cancer affecting women in the western world is breast cancer 1.
Because of the volume of women affected by this cancer, certain methods must be developed to
detect and prevent the spread of breast cancer. Methods for the latter include surgical operations
such as bilateral mastectomy or chemoprevention with the use of tamoxifen and related drugs.
Methods for the detection include clinical surveillance, ultrasound, mammography and magnetic
resonance imaging (MRI). The tests developed to detect breast cancer are rated by sensitivity and
specificity. Sensitivity relates to the tests ability to identify positive results (cancers). Specificity

relates to the ability of the test to identify negative results (non-cancers). Mammography, with a
relatively high sensitivity level, has been proven to reduce mortality rate in women with breast
cancer 2.
Although breast cancer is usually considered a sporadic disease, women with familial or
hereditary breast cancer may carry a breast cancer susceptibility gene BRCA mutation which can
give them up to 60-80% lifetime risk of breast cancer1. Prophylactic bilateral mastectomy
appears to be the most effective way to prevent breast cancer in women who have a high risk of
breast cancer1. Even for women with a BRCA gene mutation, the decision for a mastectomy is
difficult because of the emotional and mutilating effects. Current national guidelines do not
recommend mastectomy as a standard procedure for all women with BRCA gene mutation2.
Current aggressive surveillance practices for high risk women consist of mammogram and
physical examination every 6 to 12 months beginning at age 253.
Magnetic Resonance Imaging (MRI) is an option for women at high risk of breast cancer.
MRI’s have a higher biopsy rate but help to detect more cancers than mammography4.
HIBCRIT’s study on Italian women concluded that the addition of magnetic resonance imaging
to current screening regimen for women in the high risk category may enable the detection of
breast cancers that may have otherwise been missed5. MRI’s are also beneficial because
mammography is affected by breast density causing mammography tests to be less effective on
young women with denser breasts. Another advantage of MRI screening is unlike
mammography, the MRI test does not use ionizing radiation. MRI screening for breast cancer
has been deemed to be impractical for use on the general population (women without high
hereditary risk or BRCA gene mutations) because of its high cost and limited availability5. MRI
also has a low specificity rate leading to further tests and more money being spent.

Studies have been conducted to determine whether regular MRI screening has been
effective in high risk women. In a study by Moore et al, research found that although there may
be health benefits to using MRI’s, it does not appear to be cost effective at a willingness to pay
thresholds greater than 120,000/quality-adjusted life years (QALY) 6. A similar study was
conducted by Plevritis et al. in BRCA1/2 carriers. Plevritis et al. found that in that population,
MRI along with mammography is cost-effective compared to mammography alone. However,
the results vary greatly with age 7.
It is now current scientific consensus that woman with a BRCA1 or BRCA2 mutation
undergo MRI in addition to mammography8. However, little is known about the cost
effectiveness of using MRI surveillance in women without an extremely elevated risk (45-65%
lifetime risk) 6. It is this segment of the population with an average risk of developing breast
cancer that on which we conducted our research.
Methods
We created a mathematical model in an effort to determine the cost-effectiveness of
magnetic resonance imaging (MRI) versus mammography. In order to create a computer
simulation capable of determining this cost-effectiveness, we researched many factors about
breast cancer natural history and screening. Key factors include survivability, tumor size,
sensitivity and specificity of screening methods, utility weights based on quality of life years
(QALY), and cost of treatment.
Sensitivity and Specificity of Mammography and MRI Screening
To determine sensitivity and specificity, three studies were chosen because they were
split into first and subsequent MRI tests that were rated on the same BIRAD scale of 3+. These

three studies were conducted by Dr. Martin Leach and the MARBIS study group in 2005, Dr.
Mike Kriege in 2004, and Dr. Ellen Warner in 20042, 8, 9.Table 1 below gives a description of
these findings.
Table 1

Study
Sens MRI
Sensmamm
Spec MRI
Spec mamm
# of MRI screens
# of mamm screens
Total # of cancers
True positives MRI
True positive mamm
False negative MRI
False negative mamm
False positive MRI
False positive mamm
True negative MRI
True negative mamm
Found on both
Found in interval

Kreige
Warner
Leach
First Subsequent
First Subsequent
First Subsequent
.79
.62
.83
.67
.75
.67
.38
.43
.38
.43
.40
.40
.87
.92
.93
.98
.82
.81
.94
.95
.100
.100
.94
.95
1909
2260
236
221
649
1232
1909
2260
236
221
649
1232
24
21
13
9
20
15
19
13
11
6
15
12
9
9
5
3
8
6
5
8
2
3
5
3
15
12
8
6
12
9
245
179
15
5
113
231
113
112
1
0
4
73
1640
2059
208
207
516
986
1772
2127
222
222
585
1144
22
19
4
2
427
35
2
3
1
2
1
1

Table 2 consolidates this data by taking the sums and weighted averages of the
information in Table 1.
Table 2

First
Sens MRI
Sensmamm
Spec MRI
Spec mamm
# of screens
Total # of cancers
True positives MRI
True positive mamm
False negative MRI
False negative mamm
False positive MRI
False positive mamm
True negative MRI
True negative mamm
Found on both
Found in interval
False pos rate MRI
False pos rate mamm

Subsequent

.79
.39
.86
.94
2794
57
22
9
12
35
373
113
1640
158
453
4
0.134
0.057

.67
.40
.88
.95
3713
45
18
9
14
27
415
112
2059
185
56
6
0.112
0.049

Incidence
Surveillance Epidemiology and End Results, SEER10, allowed us to see the ages, races
and ethnicities that were most prone to developing breast cancer. We used the equation:

(

)

y = exp ax 2 + bx + c
where x represented age t and y represented incidence per 100,000 people. We fit the parameters
a, b and c to the SEER data stratified by age and ethnicity.
Growth of Breast Tumors

We used a modified exponential growth model to describe tumor growth. Growth was
modeled by the equation     exp



, where k represented the growth parameter that was

ln(2)/doubling time and was the volume at the time of detection by symptoms. In this modified
version of the exponential growth model, the median doubling time increased with age,
according to the equation

 0.021  2.3 , where x was age (in years) and y represented

doubling time (in years)11. Each woman has their own doubling time curve based off of a random
number drawn from a lognormal distribution. The growth parameters were chosen to match
detection rates from the Breast Cancer surveillance Consortium12. The distribution of tumor sizes
at the time of detection by symptoms came from SEER, year 198310. We then assigned a random
number to each woman to determine her tumor size at the time of detection. Within the model
tumors may also be detected at a smaller size by screening using either a mammogram or MRI.
Detection of Breast Cancer
By Symptoms - The probability of getting breast cancer by age t was given by the


equation    1  exp  

 

 , where h x is the incidence by age curve. Based on

 

the model each woman was given a random number r ranging from 0 to 1, representing her
susceptibility of acquiring breast cancer. Her age of diagnosis of breast cancer by symptoms was
represented by the age t at which P (t) = r. A woman with a random number closer to 0 would
mean that she would acquire breast cancer at a much earlier age. However, a woman with a
random number closer to 1 acquired breast cancer later on in age or not at all.
By Mammograms– The model assumes the probability of detecting a tumor on a
mammogram depends on the tumor size and the mammographic density of the breast. We use the
equation  -  1  exp .1  - / , to represent the probability of detecting a tumor on a
mammogram. The variable s represents the tumors diameter in millimeters (mm), P(s) represents

the probability of detecting the tumor on a mammogram and a1 represents a parameter of women
with dense breasts; based on women in their 40’s13. Women in this age group have an average
breast density of 40% dense tissue13. We then used a separate parameter a2 based of BCSC data
for women in their 60’s, which have an average breast density of 25% dense tissue12. To
calculate probability of women from other age groups, we took the average breast densities for
the ages of these women and linearly interpolated between the two probability equations.
MRI’s– Similarly to mammograms, we assumed that the probability of detection
increases with tumor size and used the equation  -  1  exp .3  - / . We fit this
parameter to sensitivity data from three analysis that reported on data incidence and prevalence
in high risk women undergoing mammograms and MRI’s5, 8, 14.Details about the sensitivity and
specificity analysis can be seen in Table 1 and Table 2.
Survival
We assumed that the probability of survival from breast cancer decreased with increasing
tumor size. The rate that survival decreased depended on the time since detection and varied by
race and ethnicity. R Studio used to carry out a proportional hazard analysis; stratified by both
race and ethnicity, with the natural log of the tumor diameter 15. We obtained information on
tumor size from SEER; data set 18 from years 1988 – 200310. For tumors of average size we
modeled survival with the equation  exp

012
31

, where x is the time since diagnosis and y is

the probability of survival. The relative risk of dying as a function of tumor size was given by the
equation rr = exp(beta*(ln(diameter) – mu)), where mu was the average of ln(diameter) at
detection, and beta represents the coefficient from the proportional hazards model. The final
equation for survival was P = exp((a*x + b)/(c*x + 1))^exp (beta*(ln(diameter) – mu)).

Mortality
We went to the Centers for Disease Control (CDC) website and selected data from 2001
– 2010, using 5 year age groups, stratified by gender, race16. Using Excel and R Studio we
graphed the mortality and fit the equation:

; where x represented age and y represented

mortalities per 100,000.
A similar process was used to determine mortality from other causes. We fit an
exponential curve to the CDC data for breast cancer mortality for women, stratified by race. The
data set that we obtained this information from was CDC years 2001 – 201016. The equation that
we set the information to was

 .  exp 45 with age represented byx and breast cancer

deaths per 100,000 women represented by y. Parameters a and b depended on gender, race and
origin. Mortality from other causes besides breast cancer is the difference between mortality
from all causes and mortality from breast cancer.
Utility Weights
To determine an accurate set of utility weights we went to the Tuft University Cost
Effectiveness Analysis (CEA) Registry17and used the basic search with the search term “breast
cancer” with the utility weights clicked. Over 20 pages of utility weights matched our search.
Each utility weight from 2003 onward was analyzed and ranked according to how relevant it was
to how we wanted our model to be set up, which was by stages of breast cancer or by the time
since diagnosis. The article by Dr. Schousoe which divided up the cancers into stages and first
year vs. subsequent years seemed to be most conducive to the goals of our simulation because
these factors significantly affected the cost of treatment 18. Schousboe’s article referenced
another article, “Health related Quality of Life in Different States of Breast Cancer”, by Dr.

Lidgren19. Ledgren’s article surveyed individuals in a time trade off scenario as well as an EQ5D model. We chose our utilities for our simulation to be the means from the EQ-5D model. The
means for first year after primary breast cancer, subsequent years of primary breast cancer and
metastatic diseases were .686, .776, and .689 respectively 19.
Cost of Treating Breast Cancer
To find the cost of treating breast cancer we did a Google Scholar search with the term
‘Cost of treating breast cancer in the United States’20. The most promising result was a review
article by Dr. Campbell titled, “The costs of treating breast cancer in the US: a synthesis of
published evidence”21. This article yielded Table 3. Campbell’s article reviewed and compiled 8
different studies based on cost of treating breast cancer in the initial 6 months, continued
treatment and terminal 6 months of breast cancer. Because many of these studies are dated and
the currency is not equivalent each section was put into the perspective of 2012 United States
dollars (USD) by using “Tom’s Inflation Calculator”22which is based on the Consumer Price
Index 23. To find each value in 2012 USD, the cost at the base line year, the base line year, and
2012 were entered in the calculator along with highlighting the option of ‘U.S Medical Inflation
(1935-2012)’. Each value was recorded in Table 2. The medians for the cost of initial 6 months
of treatment was were $20,821.31, the cost of continued treatment per 6 months was $4,445.72
and the cost of 6 months prior to termination was $63,202.45. In this simulation, the cost of
continued treatment was applied for 5 years after initial year of treatment.

Table 3

Study
Baker
Tplin
Legorreta
Riley
Fireman
McDonough
Barnett
Barlow
Warren
Lamerato
Median

Year
Initial
Subsequent Final
1984
6,663.98
33,583.70
1989 25,965.56
1,504.68
1989 20,821.31
1990 22,700.96
3,993.61 128,488.50
1992 32,151.08
4,897.82
76,973.22
1995 17,099.24
9,130.88
69,683.64
1997
151,767.69
1998 14,561.92
56,721.26
1998 12,175.48
40,293.69
2003 57,237.53
33,070.72
20,821.31
4,445.72
63,202.45

**Note: Initial refers to cost in USD for the first 6 months of diagnosis, Subsequent refers to cost
of continuing treatment in USD for 6 month intervals and Final is the cost of treating the last 6
months on life in USD.

Cost of Mammography and MRI screening
To determine the cost of mammography and MRI screening, the Physician Fee Schedule
Search from the Centers of Medicare and Medicaid Services (CMS) was employed24. In the
Physician Fee Schedule Search the criteria we used was 2012A year, pricing information, single
Healthcare Common Procedure Coding System (HCPCS) or Current Procedural Terminology
(CPT) code, all carriers, the corresponding HCPCS code for the individual test and all modifiers.
The search yielded a cost for a digital mammography screening test $81.35 and the cost for MRI
screening to be $787.23. The corresponding HCPCS/CPT numbers were 77057 and 7705
respectively.
Using the R-Studio simulation
To create a computer simulation able to run clinical trials on groups of 100,000 women
the computer software R Studio was used 15. Into the input 3 arms were created each running
simulated cohorts of 100,000 women. In these arms future cost and QALYs were discounted by

a factor of 0.03. In the first arm the simulation gave women a mammogram every year from age
40 to 80 which is the current recommendation for women that have an average risk of developing
breast cancer in their lifetime 3. The second arm is using MRI screening only from age 40 to age
80. Arm 3 alternates between mammography and MRI every year from age 40 to 80. These
arms were simulated using the actual cost of mammography and MRI and then used adjusted
costs to determine the price for MRI screening that would make it cost-effective compared to
mammography in terms of cost per QALY. All other variables remained the same throughout the
tests
Results
Each clinical trial consisted of three arms. Arm 1 is mammography only from 40 to 80
yearly, arm 2 is MRI only from 40 to 80 yearly, and arm 3 is mammography and MRI alternating
years from 40 to 80. “Number” on the y-axis refers to the difference in the number of QALYs
and “Time” refers to years. MRI screening was able to preserve QALYs however it proved to be
more costly as seen in Figure 1 and Figure 2.

Figure 1

Figure 1 shows how when screening begins at age 40, the trials with MRI (Arm 2) only
and MRI and mammogram (Arm 3) drop lower than the QALYs of the trial of mammography
only (Arm 1). This can be explained by MRI’s detecting more cancers in younger women, and
when these women discover they have cancer their QALYs lower form 1to what was discovered
in our utility weights for first year after primary breast cancer to be .686 19.However, as time
goes on and more breast cancers are being discovered by the mammogram only trial and less
metastatic cases are present in the MRI and MRI and mammogram trial, these QALY’s end up
being higher when being compared to the mammography only arm. The MRI only arm reaches
.018 more than the mammogram arm and the MRI and mammogram arm reaches .010 (Table 4).

Figure 2

The costs in Figure 2 demonstrate how MRI only (Arm 2) is more expensive than MRI
and mammography (Arm 3) and mammography only (Arm 1). The costs begin to differentiate
themselves at age 40 when the screening begins and stay steadily different until age 80 when
screening ends.

We used the incremental cost-effectiveness ratio (ICER) in an effort to compare
screening strategies of MRI and mammogram. Our ICER was the difference between costs
divided by the difference of QALY. The comparison of ICER values for differing prices of MRI
screens are shown in Table 4.

Table 4

Sample*
Standard Costs**
MRI 2x cost of mamm
MRI 1.5x cost of mamm
MRI same cost as mamm

MRI only vs. mammography
only
Cost
QALY ICER
14984
0.018 842,297
2018
0.018 113,452
1174
0.018 65,990
329
0.018 18,515

MRI and mammogram vs.
mammography only
Cost
QALY ICER
7458
0.010 749,131
1094
0.010 109,863
679
0.010 68,234
265
0.010 26,593

*Sample consists of 100,000 individuals each arm
**Standard costs are $81.35 per mammogram and $787.23 per MRI
The ICER value decreases as the cost of MRIs decreases. This is logical because as the
difference in cost of MRIs decreases, the total breast cancer cost decreases and the difference in
QALYs is not affected by cost.
Table 5
BC* diagnosed
Mammography only
0.116
Mammography and MRI
0.117
MRI only
0.118

BC deaths
0.018
0.016
0.015

False Positives
2.80
3.58
3.83

*breast cancer
**Result per person
***Sample consists of 100,000 individuals in each arm

The use of MRI screening allows for more diagnoses of breast cancer and less deaths by
breast cancer. However, the number of false positives in the mammogram only trial is less that
the false positive rate in the Mammography and MRI and the MRI only trial.

Table 6

Screening
cost ($)/%
of total
Mammogram only Standard Cost**
Mammogram only Same Cost***
MRI and Mammogram Standard Cost
MRI and Mammogram Same Cost
MRI only Standard Cost
MRI only Same Cost

1693/ 20
1693 / 20
8897 / 56
1705 / 20
16344 / 70
1689 / 19

False
Positive
Cost ($)/%
of total
900 / 11
900 / 11
1108 / 7
1108 / 13
1161 / 5
1160 / 13

Cost of
treatment
($)/% of
total
3985 / 47
3985 / 47
4028 / 25
4028 / 46
4053 / 17
4053 / 46

Death cost
($)/% of
total

Total
Cost
($)

1868 / 22
1868 / 22
1872 / 12
1872 / 21
1873 / 8
1874 / 21

8447
8447
15904
8711
23431
8777

*data based on dollars per person of 100,000 sample
** Standard screening costs are $81.35 per mammogram and $787.23 per MRI
***Same cost were $81.35 per mammogram and $81.35 per MRI

For the use of mammography screening only, the primary cost involved is the cost of
treatment. However, when MRI is used alone or with mammography screening the major cost is
the screening. The cost of MRI screening is causing a large cost difference between
mammography screening and MRI plus mammography and MRI alone. Note that even when
MRIs cost the same as mammograms, the MRI arm has higher total costs than the mammogram
arm. This is primarily due to the increased number of false positives that are associated with
MRI’s and partially due to MRI’s ability to detect more breast cancers earlier and therefore
increasing the treatment costs.
Discussion
Although MRI may have health benefits, based on a $100,000/QALY cost effectiveness
ratio, current prices of MRI do not support that MRI screening for women yearly from ages 40 to
80 or alternating between mammography and MRI yearly for women of the same ages as cost

effective. However, if the costs of MRI were able to come down to twice the current price of
mammography, the ICER value suggests that at a $100,000/QALY threshold, alternating MRI
and mammography screening would be cost effective. With MRI prices equal to mammography
prices, MRI alone as well as MRI with mammography screening would be cost effective even at
a $50,000/QALY ratio.
Our findings are similar to those of Susan G Moore in her 2009 study which found that
MRI screening is not cost effective at current MRI price. However, our study does not deal with
a young age population or with individuals of pre-determined high risk. Other studies such as
Pleuvertis 2006 and Lee 2010, also dealing with high risk categories, however, found the
practice of MRI screening to be cost effective in specific cases.
Weaknesses in our analysis could include that the specificity and sensitivity of our
screening techniques were determined by studies of women of high risk. The sensitivity and
specificity of these tests for women on the typical population could be different. Another
weakness in our model could be the utility weights. The current utility weights indicate that the
first year of being diagnosed with breast cancer is nearly equal to the metastatic stage which does
not seem intuitive.
Future directions of study include what level of risk makes MRI cost-effective. Since
MRI is not cost-effective for the entire population it may be useful to know what category of 5year risk would make MRI’s cost effective. Sensitivity analysis could be conducted to see the
impact of specific elements.
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